Arix Bioscience : ARIX

News

• 07 Jun 2019 2 min read

  Biotech firms brace for wave of Woodford fund liquidations

  Biotech firms brace for wave of Woodford fund liquidations Arix Biosciences (ARIX), Reneuron (RENE), Mereo Biopharma (MPH) and 4D Pharma (DDDD) look set to be among the firms braced for the potential sale of all or parts of the shareholdings held by Woodford Invesmtent Management in the coming days, as the troubled manager appears to […]

• 06 Aug 2018 2 min read

  Arix leads first VIPE into Pharmaxis

  Arix leads first VIPE into Pharmaxis LSE-quoted life science investor Arix Bioscience (ARIX) is to acquire an 11% interest in Pharmaxis (ASX: PXS) in its first VIPE or venture investment in public equity. Arix led a A$24m placing in the Australian biotech, in which it will invest A$14.2m for a 11% holding. This will mean the […]

• 03 Aug 2018 2 min read

  Arix remains highly geared to Autolus value

  Arix remains highly geared to Autolus value Arix Bioscience’s 8% investment in Autolus Therapeutics (Nasdaq: AUTL), the recently floated second-generation CAR-T company, now accounts for more than half of the value of its investments, some 25% of its NAV and almost 30% of its stockmarket value, according to calculations by Marten & Co. Arix is by far […]

• 24 Jul 2018 1 min read

  Autolus jumps to top of Woodford Patient Capital

  Autolus jumps to top position in Woodford Patient Capital Trust Woodford Patient Capital Trust (WPCT)’s stake in Autolus, the UK second generation CAR-T therapy company, rose by six places to top position in the portfolio in June, according to WPCT’s latest factsheet. The rise reflects Autolus’ recent IPO, which was priced at a valuation considerably above […]

• 25 Jun 2018 2 min read

  Arix, Syncona and WPCT bank gains after Autolus “pops” on Nasdaq IPO

  Arix,  Syncona and WPCT bank gains after Autolus “pops” on Nasdaq IPO Arix Bioscience (ARIX), Syncona (SYNC) and Woodford Patient Capital Trust (WPCT) should be able to record some sizeable NAV gains this month, as previously highlighted in earlier Quoteddata.com articles, on the back of a revaluation to market value of their respective holdings in the common portfolio […]

• 14 Jun 2018 1 min read

  Arix, Syncona and WPCT look set to reap gains on pending Autolus IPO

  Arix, Syncona and WPCT look set to reap gains on pending Autolus Nasdaq IPO Three LSE-listed health/biotech venture capital investment firms – Arix Bioscience (ARIX), Syncona (SYNC) and Woodford Patient Capital Trust (WPCT) – should see a nice boost to their NAV if Autolus, the UK-based CAR-T cell company completes its proposed Nasdaq IPO. Autolus is a portfolio company for […]

• 06 Mar 2018 2 min read

  UK Life science VC investors cheer planned IPO of Autolus

  UK Life science VC investors cheer planned IPO of Autolus Three high-profile UK life science investors – Syncona (SYNC), Arix Bioscience (ARIX) and Woodford Patient Capital Trust (WPCT) – could benefit from the possible US IPO of the engineered T-cell therapy company, Autolus, following that company’s disclosure yesterday of a filing of a confidential draft F1 submission. All three investors hold […]

• 12 Dec 2017 1 min read

  UK CAR-T firm Autolus provides update at ASH conference

  UK CAR-T firm Autolus provides update at ASH conference Autolus, which is a closely-watched chimeric antigen receptor T-cell therapy firm backed by three of the UK’s most prominent biotech investors, obtained an important validation of its technology recently with the publication of data on its dual targeting technology at the American Society of Hematology (ASH) conference over […]